Cancer cells can evade immune surveillance by expressing multiple immune-checkpoint proteins, such as programmed cell death ligand 1 (PD-L1), CD80/86, and Gal9, which inhibit T-cell activation and proliferation [79,80]. Here, CD274 is linked to cancer.